
FDA approves use of biosimilar insulin as automatic substitute for costly brand-name
CBSN
U.S. regulators took action Wednesday that should make it easier to get a cheaper near-copy of a brand-name insulin at the drugstore.
Doctors must now prescribe what's called a biosimilar drug, or OK its use as a substitution for a more expensive brand-name insulin. The Food and Drug Administration has given its approval to Semglee, the first biosimilar cleared as a substitute for Lantus, a widely used fast-acting insulin.
Federal regulators repeatedly granted appeals to remove Camp Mystic's buildings from their 100-year flood map, loosening oversight as the camp operated and expanded in a dangerous flood plain in the years before rushing waters swept away children and counselors, a review by The Associated Press found.

Washington — Emil Bove, a top Justice Department official who previously served as President Trump's criminal defense attorney, declined to rule out the possibility of the president running for a third term and did not denounce the Jan. 6 attack on the Capitol in a questionnaire submitted to a Senate panel considering his nomination for a lifetime appointment as a federal judge.